Quest Diagnostics (DGX) Reports In-Line Q1 EPS; Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mizuho Securities Raises Price Target on Quest Diagnostics (DGX) Following In-Line 1Q Results
April 21, 2016 2:16 PM EDTMizuho Securities reiterated an Outperform rating on Quest Diagnostics (NYSE: DGX), and raised the price target to $84.00 (from $75.00), following the company's 1Q earnings report. DGX reported an adjusted EPS of $1.12, in-line with consensus estimates.
Analyst Ann Hynes commented, "We are raising our price... More
